Silencing the Breast Cancer Resistance Protein Expression and Function in Caco-2 Cells Using Lentiviral Vector-Based Short Hairpin RNA

被引:20
作者
Zhang, Wei [1 ]
Li, Jibin [1 ]
Allen, Samantha M. [1 ]
Weiskircher, Erica A. [1 ]
Huang, Yuehua [1 ]
George, Rebecca A. [1 ]
Fong, Ramon G. [1 ]
Owen, Albert [1 ]
Hidalgo, Ismael J. [1 ]
机构
[1] Absorpt Syst LP, Exton, PA 19341 USA
关键词
ATYPICAL MULTIDRUG-RESISTANCE; SMALL INTERFERING RNAS; STABLE EXPRESSION; COMPLETE REVERSAL; GENE-EXPRESSION; CARCINOMA-CELLS; MODULATION; ABCG2; MDR1; TRANSPORTER;
D O I
10.1124/dmd.108.023309
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A series of stable breast cancer resistance protein (BCRP, ABCG2) knockdown cell lines were produced by transduction of Caco-2 cells with lentiviral vector-based short hairpin RNA (shRNA). Caco-2 cell is a human intestinal-derived cell line widely used to study intestinal drug absorption. Caco-2 expresses three apical drug efflux transporters: BCRP, P-glycoprotein (P-gp; ABCB1), and multidrug resistance protein 2 (MRP2, ABCC2). BCRP and P-gp in particular play a significant role in pharmacokinetics because of their expression at several key interfaces. Overexpression of BCRP in cancer cells may also be a mechanism of tumor resistance to chemotherapeutic drugs. The goal of this study was to engineer and characterize Caco-2 cell clones with stable knockdown of BCRP expression. The shRNA/BCRP lentiviral particles were used to infect a stable clone of Caco-2 cells. Expression of BCRP was monitored using quantitative polymerase chain reaction (qPCR), Western blotting, immunofluorescence microscopy, and bidirectional transport of probe substrates, estrone-3-sulfate (E3S), and pheophorbide A (PhA). Based on qPCR, expression of BCRP mRNA was knocked down in five clones with a maximum of 97% silencing in clone D. Silencing of BCRP gene expression was maintained for at least 25 passages. Expression of BCRP protein was also reduced significantly. Functionally, BCRP knockdown was reflected in significant reduction of the efflux ratio of E3S and PhA. Clone D in particular should be a useful model for identifying and characterizing P-gp substrates and inhibitors without interference from BCRP and/or MRP2. In addition, it can be used in conjunction with wild-type or vector control Caco-2 cells to identify BCRP substrates.
引用
收藏
页码:737 / 744
页数:8
相关论文
共 27 条
  • [1] Caco-2 monolayers in experimental and theoretical predictions of drug transport (Reprinted from Advanced Drug Delivery Reviews, vol 22, pg 67-84, 1996)
    Artursson, P
    Palm, K
    Luthman, K
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) : 27 - 43
  • [2] A system for stable expression of short interfering RNAs in mammalian cells
    Brummelkamp, TR
    Bernards, R
    Agami, R
    [J]. SCIENCE, 2002, 296 (5567) : 550 - 553
  • [3] Burger H, 2003, CLIN CANCER RES, V9, P827
  • [4] Stable suppression of MDR1 gene expression and function by RNAi in Caco-2 cells
    Celius, T
    Garberg, P
    Lundgren, B
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (01) : 365 - 371
  • [5] Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
    Doyle, LA
    Ross, DD
    [J]. ONCOGENE, 2003, 22 (47) : 7340 - 7358
  • [6] A multidrug resistance transporter from human MCF-7 breast cancer cells
    Doyle, LA
    Yang, WD
    Abruzzo, LV
    Krogmann, T
    Gao, YM
    Rishi, AK
    Ross, DD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) : 15665 - 15670
  • [7] Ee PLR, 2004, MOL CANCER THER, V3, P1577
  • [8] Multidrug resistance and cancer: The role of the human ABC transporter ABCG2
    Ejendal, KFK
    Hrycyna, CA
    [J]. CURRENT PROTEIN & PEPTIDE SCIENCE, 2002, 3 (05) : 503 - 511
  • [9] Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization
    Kage, K
    Tsukahara, S
    Sugiyama, T
    Asada, S
    Ishikawa, E
    Tsuruo, T
    Sugimoto, Y
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 97 (05) : 626 - 630
  • [10] Kellen John A, 2003, J Exp Ther Oncol, V3, P5, DOI 10.1046/j.1359-4117.2003.01067.x